Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of preparation method of hepatitis drug intermediate

A technology of intermediates and drugs, applied in the field of preparation of drug intermediates, can solve the problems of expensive, difficult recycling, expensive catalysts, etc., and achieve the effects of less side reactions, high yield, and low requirements for reaction conditions

Active Publication Date: 2022-03-08
SUZHOU JINGYE MEDICINE & CHEM
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The disadvantage of this method is that the procurement of starting materials is difficult and expensive
At the same time, after a multi-step reaction, the chlorine in the molecule needs to be converted into a substituted amino group. The substitution reaction requires the use of 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene, Tris(dibenzylideneacetone) dipalladium (0) catalyst, which is expensive and difficult to recycle, thus resulting in high production costs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of preparation method of hepatitis drug intermediate
  • A kind of preparation method of hepatitis drug intermediate
  • A kind of preparation method of hepatitis drug intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Embodiment 1: Preparation of 3-fluoroacetanilide

[0040]

[0041] Add 220ml of acetic acid and 55.5g (0.5M) of m-fluoroaniline into a 500ml four-neck bottle, stir to form a homogeneous one, and slowly add 53.6g (0.525M) of acetic anhydride (with obvious temperature rise). After the addition, heat up to 105°C. Insulation reaction 2hrs.

[0042] After the heat preservation is over, remove the acetic acid and acetic anhydride under reduced pressure, and remove to 110°C (-0.095MPa). Slightly cool to 85°C, add 55g of ethyl acetate, stir until uniform, and cool. Cool to room temperature, add 110g of n-hexane dropwise, freeze after dropping, cool to 0°C, stir for 2hrs to crystallize. Suction filtration, washing with n-hexane, and drying to obtain 75.0 g of partial solids, and 3-fluoroacetanilide with a content of more than 99.5% and a yield of about 98%.

Embodiment 2

[0043] Embodiment 2, the preparation of 2-fluoro-4-acetamidoacetophenone

[0044]

[0045] Add 104g of anhydrous aluminum trichloride (0.78M) and 150ml of carbon disulfide to a 500ml four-necked bottle, stir and cool to 0°C, slowly add 39.3g of acetyl chloride (0.5M), after the addition, raise the temperature to 20°C, and stir for 30min . Freeze to 0°C, and add 30.6 g (0.20 M) of m-fluoroacetanilide in batches. After the addition, the temperature was raised to room temperature and stirred for 30 min. Then heated to reflux for 48hrs.

[0046]After reflux, cool to room temperature. Remove the supernatant (to recover carbon disulfide), pour the reaction solution into 500g of crushed ice and 50ml of hydrochloric acid, and stir for hydrolysis. The hydrolyzate was extracted twice with 150ml and 100ml dichloroethane. The extracts were combined and washed twice with 100ml×2 water. The organic phase is a dichloroethane solution of the F-C product.

[0047] The solvent was rem...

Embodiment 3

[0048] Embodiment 3, the preparation of 2-fluoro-4-acetamidoacetophenone

[0049] According to the method in Example 2, nitrobenzene was used instead of carbon disulfide as a solvent. After the reaction was over, it was cooled, poured into crushed ice, stirred and hydrolyzed, and then the organic layer was separated, dried over sodium sulfate, and nitrobenzene was recovered by distillation under reduced pressure. Appropriate amount of methyl chloride, heated to dissolve. Cool to room temperature, slowly add n-hexane dropwise, stir for 1 hr (around 25°C), filter with suction, and wash with dichloromethane / n-hexane (1 / 3). The solid was dried to obtain the Fuke acylation product with a content of more than 97%. Yield 60.1%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a preparation method of a hepatitis drug intermediate, which is characterized in that m-fluoroaniline is used as a starting material, and after acetylated amino protection, Friedel-Crafts acylation reaction, nitration reaction, bromination reaction, and finally coupling to obtain 1,4‑bis‑[(4‑acetamido‑2‑fluoro‑5‑nitro)phenyl]butane‑1,4‑dione. The present invention has easy-to-obtain raw materials, low requirements on reaction conditions, few side reactions, and high yield. 1,4-bis-[(4-acetamido-2-fluoro-5-nitro)phenyl]butane-1,4 -Diketones can be used as pharmaceutical intermediates for the preparation of pirentasvir.

Description

technical field [0001] The present invention relates to a preparation method of a pharmaceutical intermediate, in particular to the preparation of 1,4-bis-[(4-acetylamino-2-fluoro-5-nitro)phenyl]butane-1,4-dione method. Background technique [0002] Hepatitis C is considered to be a chronic liver viral disease. Mavyret, a pan-gene hepatitis C compound drug launched by American biotechnology giant AbbVie, is used to treat all 6 genotypes (GT1-6) of chronic hepatitis C virus ( HCV) adult patients, the drug treatment course is 8 weeks. After HCV patients take Maviret according to the course of treatment, the virological cure rate reaches 98%. [0003] Mavyret is a compound composed of an NS3 / 4A protease inhibitor glecaprevir and an NS5A inhibitor pibrentasvir, among which pibrentasvir is a new compound that is listed for the first time. The synthesis method of pirentasvir reported in the literature (WO2012051361A1) is to use 4-chloro-2-fluoro-5-nitrobenzoic acid as a raw mat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07C231/12C07C233/43
CPCC07C231/12C07C231/02C07C233/43C07C233/33C07C233/15
Inventor 沈建伟吴和明
Owner SUZHOU JINGYE MEDICINE & CHEM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com